Bone Affecting Patents (Class 514/16.7)
-
Patent number: 11925722Abstract: The present invention relates to a composition of a calcium phosphate such as tetracalcium phosphate or ?-TCP and an additive compound selected from nucleic acid or nucleotides, phospho(enol)pyruvic acid and phosphocreatine. The composition may be used as a tissue adhesive.Type: GrantFiled: November 30, 2018Date of Patent: March 12, 2024Assignee: GPBIO LTD.Inventors: Philip Procter, Michael Pujari-Palmer, Gerard Insley, Håkan Engqvist
-
Patent number: 11780901Abstract: Described are polypeptide analogs of parathyroid hormone (PTH) that include an unnatural amino acid substitution at positions 7 or 8 from the N-terminus of the polypeptide. Also described are pharmaceutical compositions useful for treating hypoparathyroidism that contain the analogs and methods of using the analogs to treat hypoparathyroidism.Type: GrantFiled: September 24, 2020Date of Patent: October 10, 2023Assignees: Wisconsin Alumni Research Foundation, The General Hospital CorporationInventors: Samuel H. Gellman, Shi Liu, Thomas J. Gardella
-
Patent number: 11766332Abstract: An implantable mesh including demineralized bone fibers mechanically entangled into a biodegradable or permanent implantable mesh is provided. A method of preparing the implantable mesh is also provided. The method of preparing the implantable mesh includes mechanically entangling demineralized bone fibers with non-bone fibers to form the implantable mesh. The mechanical entanglement of the bone fibers into the implantable mesh is achieved by applying needle punching with barbed needles, spun lacing, entanglement with water jets or air jets or ultrasonic entanglement with ultrasonic waves. A method of implanting an implantable mesh at a target bone tissue site is also provided.Type: GrantFiled: September 24, 2020Date of Patent: September 26, 2023Assignee: Warsaw Orthopedic, Inc.Inventor: Kelly W. Schlachter
-
Patent number: 11617814Abstract: Described herein are polymeric particles configured for intravascular delivery of pharmaceutical agents, e.g., to a diseased site, and methods of forming and using same. Preparation of these polymer particles is also described.Type: GrantFiled: June 26, 2020Date of Patent: April 4, 2023Assignee: Terumo CorporationInventors: Gregory M. Cruise, Xinping Wu, Gloria Hincapie, Yue Wu
-
Patent number: 11492382Abstract: Provided in this disclosure are chimeric peptides that include a spacer domain, the spacer domain itself, substrates (e.g., implants) coated with the chimeric peptides, and methods for making and using the coated substrates.Type: GrantFiled: August 21, 2018Date of Patent: November 8, 2022Assignee: UNIVERSITY OF KANSASInventors: Candan Tamerler-Behar, Emily Caitlyn Wisdom, Kyle Boone
-
Patent number: 11253628Abstract: This disclosure relates to methods for promoting bone formation or reducing bone destruction. This disclosure also relates to methods for promoting the recruitment of mesenchymal stem cells (MSCs) to a local site of injury or surgical intervention in bone to promote healing. In addition, this disclosure relates to methods for reducing or preventing mineral formation or bone growth, or reducing bone mass. The methods disclosed herein are useful for treating conditions such as osteopetrosis or osteoradionecrosis.Type: GrantFiled: April 19, 2019Date of Patent: February 22, 2022Assignee: The Research Foundation for the State University of New YorkInventors: Bryan S. Margulies, Sean D. Deboyace
-
Patent number: 11241502Abstract: The present invention provides stable pharmaceutical compositions of pegylated carfilzomib compounds, methods for preparing the compositions, and uses of the compositions for treating cancer, including hematologic malignancies such as multiple myeloma. The compositions can be stored in frozen form or lyophilized to dry solid form.Type: GrantFiled: November 15, 2018Date of Patent: February 8, 2022Assignee: AMGEN INC.Inventors: Alona Teran, William Callahan, Qahera Munaim, Rahul Kaushik
-
Patent number: 11224661Abstract: The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.Type: GrantFiled: January 5, 2017Date of Patent: January 18, 2022Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Kennett Sprogøe, Harald Rau, Ana Bernhard, Ulrich Hersel, Felix Cleenmann, Thomas Wegge
-
Patent number: 10960108Abstract: A method of making a bone matrix includes exposing a bone tissue to a solution including a surfactant and a protease; treating the bone tissue with an acid solution following exposing the bone tissue; and electrophoretically treating the acid treated bone tissue. A bone matrix has a DNA content of not greater than 0.1 micrograms per milligram sample and a modulus in a range of 180 kPa to 250 kPa.Type: GrantFiled: June 14, 2018Date of Patent: March 30, 2021Assignee: FABRICO TECHNOLOGY INCInventors: Joseph Oleniczak, Robert Chin
-
Patent number: 10918629Abstract: The disclosure relates to the field of lymphedema therapy, more specifically, to a new pharmacological strategy to rescue the failed lymph pump system that can supplement, enhance or replace current therapies.Type: GrantFiled: October 20, 2015Date of Patent: February 16, 2021Assignee: The Curators of the University of MissouriInventor: Michael John Davis
-
Patent number: 10864194Abstract: The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.Type: GrantFiled: June 8, 2017Date of Patent: December 15, 2020Assignee: Clementia Pharmaceuticals Inc.Inventors: Clarissa Desjardins, Donna Roy Grogan, Jeffrey Neal Packman, Mark Harnett
-
Patent number: 10688178Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.Type: GrantFiled: June 30, 2016Date of Patent: June 23, 2020Assignees: Osaka University, Chugai Seiyaku Kabushiki KaishaInventors: Atsushi Kumanogoh, Ryusuke Omiya, Hiroyuki Tsunoda, Takeshi Baba, Sachiyo Suzuki, Yuri Teranishi
-
Patent number: 10610506Abstract: The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.Type: GrantFiled: February 10, 2017Date of Patent: April 7, 2020Assignee: UCL BUSINESS LTDInventors: Rajiv Jalan, Kamal Nayan Jalan
-
Patent number: 10548923Abstract: A method of enhancing the binding of growth factors and cell cultures to a demineralized allograft bone material which includes applying ex vivo an effective quantity of an ionic force change agent to at least a portion of the surface of a demineralized allograft bone material to produce a binding-sensitized demineralized allograft bone material and implanting the binding-sensitized demineralized allograft bone material into a host bone. The ionic force change agent may include at least one of enzymes, pressure, chemicals, heat, sheer force, oxygen plasma, supercritical nitrogen, supercritical carbon, supercritical water or a combination thereof. A molecule, a cell culture, or a combination thereof is administered to the binding-sensitized demineralized allograft bone material.Type: GrantFiled: September 13, 2017Date of Patent: February 4, 2020Assignee: Warsaw Orthopedic, Inc.Inventors: Guobao Wei, Susan J. Drapeau
-
Patent number: 10550165Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.Type: GrantFiled: August 30, 2017Date of Patent: February 4, 2020Assignees: STEMRIM INC., OSAKA UNIVERSITYInventors: Katsuto Tamai, Takehiko Yamazaki, Tsutomu Kanezaki, Shigeru Sakurai, Yukiko Noguchi, Mayumi Endo, Natsumi Hamabuchi, Kana Naito
-
Patent number: 10485853Abstract: The invention relates to a cheese includes angiogenin and/or angiogenin hydrolysate in an amount of 6.5 mg/100 g to 160 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 33.Type: GrantFiled: July 31, 2012Date of Patent: November 26, 2019Assignee: MEGMILK SNOW BRAND CO., LTD.Inventors: Aiko Ohmachi, Hiroaki Matsuyama, Yoshikazu Morita, Yuko Ishida, Takayuki Nara, Ken Kato, Atsushi Serizawa, Hiroshi Ueno, Hiroshi Urazono
-
Patent number: 10406264Abstract: The present invention relates to a peptide having the ability to bind specifically to the surface of titanium. The titanium-binding peptide according to the present invention is fixed securely to the titanium surface so that the activity of a physiologically active substance linked to the peptide can be stably maintained over a long period of time. Thus, the peptide can be effectively used for surgical regeneration therapy.Type: GrantFiled: March 7, 2017Date of Patent: September 10, 2019Assignees: NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO., LTD., Seoul National University R&DB FoundationInventors: Chong-Pyoung Chung, Yoon Jeong Park, Jue-Yeon Lee, Yeonsu Kim, Dong Woo Lee
-
Patent number: 10385104Abstract: The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.Type: GrantFiled: January 11, 2018Date of Patent: August 20, 2019Assignees: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY, THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.Inventor: Varda Shoshan-Barmatz
-
Patent number: 10350188Abstract: Use of Neu1 sialidase inhibitors for the treatment of cancer as a monotherapy or in combination with known chemotherapeutics. Preferably, Neu1 sialidase inhibitors are oseltamivir phosphate or 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA) or analogs thereof.Type: GrantFiled: November 4, 2011Date of Patent: July 16, 2019Inventors: Paul Zachary Josefowitz, Constantin Melas-Kyriazl, Myron R. Szewczuk
-
Patent number: 10213527Abstract: An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.Type: GrantFiled: August 3, 2017Date of Patent: February 26, 2019Assignee: Ben-Gurion University of the Negev Research and Development AuthorityInventors: Hanna Rapaport, Anna Gittelman
-
Patent number: 10017766Abstract: The invention relates to si RNA molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the FLAP gene. The invention also relates to the use of said si RNAs molecules in the treatment and/or prevention of an eye condition characterized by increased expression and/or activity of FLAP gene, preferably said eye condition is conjunctivitis and/or an ocular allergy such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis.Type: GrantFiled: October 21, 2014Date of Patent: July 10, 2018Assignee: SYLENTIS SAUInventors: Ana Isabel Jimenez, Covadonga Pañeda, Tamara Martinez
-
Patent number: 9951103Abstract: There is described a material comprising tapes, ribbons, fibrils or fibers characterized in that each of the ribbons, fibrils or fibers have an antiparallel arrangement of peptides in a ?-sheet tape-like substructure.Type: GrantFiled: March 16, 2017Date of Patent: April 24, 2018Assignee: University of LeedsInventors: Neville Boden, Amalia Aggeli, Eileen Ingham, Jennifer Kirkham
-
Patent number: 9884072Abstract: Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.Type: GrantFiled: January 9, 2017Date of Patent: February 6, 2018Assignee: Ionis Pharmaceuticals, Inc.Inventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier, Marc Lim, Andrew Dibble
-
Patent number: 9566257Abstract: The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.Type: GrantFiled: June 13, 2012Date of Patent: February 14, 2017Assignee: UCL Business PLCInventors: Rajiv Jalan, Kamal Nayan Jalan
-
Patent number: 9555053Abstract: The present invention relates to a compound selected among the synthetic polysulphated oligosaccharides having 1 to 4 ose units and the salts and complexes thereof to be used for the treatment of wounds resulting in pathological scars selected among hypertrophic, retractile or atrophic scars. Said use is preferred in particular in patients that have a predisposition to developing hypertrophic, retractile or atrophic scars. According to a second aspect, the invention also relates to said compound for the use thereof in order to inhibit the differentiation of fibroblasts into myofibroblasts during the cicatrisation of wounds resulting in pathological scars selected among hypertrophic, retractile or atrophic scars.Type: GrantFiled: July 12, 2012Date of Patent: January 31, 2017Assignees: LABORATOIRES URGO, SOCIETE DE DEVELOPPEMENT ET DE RECHERCHE INDUSTRIELLEInventors: Marielle Bouschbacher, Christelle Laurensou
-
Patent number: 9512404Abstract: The present invention relates to nanofibers. In particular, the present invention provides aligned nanofiber bundle assemblies. In some embodiments, the aligned nanofiber bundle assemblies are used for tissue regeneration, controlled growth of cells, and related methods (e.g., diagnostic methods, research methods, drug screening).Type: GrantFiled: July 8, 2014Date of Patent: December 6, 2016Assignee: Northwestern UniversityInventors: Samuel I. Stupp, Shuming Zhang, Alvaro Mata, Megan A. Greenfield
-
Patent number: 9393287Abstract: Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or fetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analog, derivative thereof, or combinations thereof, or otherwise, at least one nucleic acid molecule encoding colony stimulating factor-1 protein (CSF-1), precursor, variant, analog, derivative thereof, or combinations thereof.Type: GrantFiled: March 19, 2014Date of Patent: July 19, 2016Assignee: KINTAN PTY LTD.Inventors: Sharon Denise Ricardo, David Arthur Hume, Melissa Helen Little, Christina Victoria Jones
-
Patent number: 9393270Abstract: A vacuum container supports a macroscopic sized cancellous device fully immersed within a solution of a bone growth promoting substance in a sealed chamber. The solution may include one of a Demineralized Bone Matrix (DBM) solution, a morphegenic protein solution, or a stem cell solution. A vacuum creating device is in fluid communication with the sealed chamber, and is operable to remove air from within the sealed chamber to create a vacuum therein. Removing air from the sealed chamber also removes air from a plurality of voids in the cancellous device, which allows the solution to fill the voids and saturate the cancellous device in preparation for use as a bone graft. The cancellous device may further be agitated while the air is being removed from the voids in the cancellous device to further promote saturation of the voids in the cancellous device with the solution.Type: GrantFiled: July 20, 2015Date of Patent: July 19, 2016Inventor: Vittorio M. Morreale
-
Patent number: 9333237Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: April 28, 2014Date of Patent: May 10, 2016Assignees: The United States of America National Institutes of Health (NIH), U.S. Dept of Health and Human Services (DHHS), The Regents of the University of CaliforniaInventors: Samuel S. Murray, Elsa J. Murray, Keyvan Behnam
-
Patent number: 9155746Abstract: Disclosed herein are methods of promoting osteogenesis in a subject, comprising administering a composition comprising a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA). Also disclosed herein are methods of promoting osteogenesis in a subject in need of such promotion, comprising administering a composition comprising a therapeutically effective amount of at least one CSA. Additionally, disclosed herein are compounds and compositions comprising at least one CSA, or a pharmaceutically acceptable salt thereof, for use in the treatment of bone disease or the treatment of broken bones. Kits comprising such compositions and instructions on such methods are also contemplated herein.Type: GrantFiled: September 13, 2012Date of Patent: October 13, 2015Assignee: Brigham Young UniversityInventors: Carl Genberg, Paul B. Savage
-
Patent number: 9095551Abstract: An object of the present invention is to enable the repair and regeneration of articular cartilage, which could not be achieved by conventional therapies, and to provide a safe and inexpensive agent that is effective for the treatment of joint diseases such as osteoarthritis. According to the present invention, a combined formulation for simultaneously, separately, or sequentially administering a hyaluronic acid and an animal mucin-type glycoprotein for the treatment of joint diseases is provided.Type: GrantFiled: January 29, 2010Date of Patent: August 4, 2015Assignees: RIKEN, TOKAI UNIVERSITY EDUCATIONAL SYSTEMInventors: Kiminori Ushida, Koji Kihira, Takayuki Baba, Kayoko Taniguchi, Makoto Urai, Masato Sato, Naoshi Ohta, Joji Mochida
-
Patent number: 9068016Abstract: The present invention provides conjugates of cytokines and targeting peptides that is able to bind to a receptor expressed on tumor-associated vessels or to a component of the extracellular matrix associated to the tumor vessels, for treatment of malignant pleural mesothelioma. In particular, the invention provides conjugates comprising the cytokine TNF linked to a peptide containing the NGR motif. The invention further provides pharmaceutical compositions comprising such conjugate and pharmaceutical formulations comprising conjugates dissolved in appropriate buffers.Type: GrantFiled: January 25, 2013Date of Patent: June 30, 2015Assignee: Molmed S.P.AInventors: Claudio Bordignon, Antonio Lambiase
-
Patent number: 9050300Abstract: The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired.Type: GrantFiled: April 5, 2013Date of Patent: June 9, 2015Assignees: The Regents of The University of California, The United States of America Represented by The Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Brochmann-Murray, Keyvan Behnam, Jeffrey C. Wang
-
Publication number: 20150141333Abstract: A malleable bone graft composition is described. The composition comprises: (a) keratose; (b) particulate filler; (c) antibiotic; and (d) water. The invention may be provided in sterile form in an container, and optionally lyophilized. Methods of treating a fracture with such compositions are also described.Type: ApplicationFiled: November 19, 2014Publication date: May 21, 2015Inventor: Mark E. Van Dyke
-
Publication number: 20150139907Abstract: This invention provides novel methods for inducing hair growth and/or inhibiting hair loss and/or inducing nail growth in a mammal. In various embodiments the methods involve administering, e.g., to a mammal in need thereof, a calcium-binding peptide and/or peptide-like moiety in an amount sufficient to induce hair growth and/or to inhibit hair loss. In certain embodiments the agent is topically and/or transdermally administered.Type: ApplicationFiled: October 14, 2014Publication date: May 21, 2015Inventors: Daniel K. Yarbrough, Xiaoyang Wu, Wenyuan Shi, Maxwell H. Anderson
-
Publication number: 20150133367Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.Type: ApplicationFiled: April 26, 2013Publication date: May 14, 2015Inventor: Doron C. Greenbaum
-
Publication number: 20150126452Abstract: The present invention relates to a method for assembling (monomeric or oligomeric) proteins and peptide structures to multimeric protein or peptide structures. The present invention also provides a method for preparing peptide based polymers by crosslinking such multimeric proteins or peptides obtainable according to the inventive method and their use as polymers, for amphiphilic applications, as protein based detergents, for forming artificial organelles, etc. Disclosed are furthermore novel protein or peptide structures, nucleic acids encoding same and cloning and expression vectors suitable for carrying out the inventive method for assembling multimeric proteins or peptides.Type: ApplicationFiled: May 28, 2013Publication date: May 7, 2015Inventors: Stefan Schiller, Matthias Huber
-
Publication number: 20150125537Abstract: There is provided a bone filler material comprising a plurality of particles, each particle comprising a biodegradable outer shell and an inner core. There is also provided an implant prepared from the same, methods of using the same and preparing the same.Type: ApplicationFiled: November 7, 2014Publication date: May 7, 2015Inventors: Cho Hong James Goh, Pujiang Shi, Hee Kit Wong, Yong Zhang, Sunny Akogwu Abbah, Jun Li
-
Publication number: 20150119334Abstract: An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.Type: ApplicationFiled: June 3, 2013Publication date: April 30, 2015Applicant: Ben-Gurion niversity of the Negev Research and Development AuthorityInventors: Hanna Rapaport, Anna Gittelman
-
Patent number: 8999935Abstract: The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves selecting a peri- or post-menopausal female subject in need of treating, preventing, or reducing the risk of bone deterioration or osteoporosis and administering hepcidin to the selected subject under conditions effective to treat, prevent, or reduce the risk of bone deterioration or osteoporosis.Type: GrantFiled: February 11, 2010Date of Patent: April 7, 2015Assignee: New York UniversityInventor: Xi Huang
-
Patent number: 8987201Abstract: Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming cell; reducing apoptosis in a bone-forming cell; decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a bone-forming cell; increasing the expression level of one or more of a bone matrix protein, a transcriptional activator, or a transcriptional regulator in a bone-forming cell; enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a subject; also provided are antibodies directed against black bear parathyroid hormone (PTH) and functional fragments thereof.Type: GrantFiled: December 7, 2009Date of Patent: March 24, 2015Assignee: Michigan Technological UniversityInventor: Seth W. Donahue
-
Patent number: 8987203Abstract: The present invention relates to methods for selecting a candidate therapeutic agent for controlling mineralization of an extracellular matrix in a tissue of a subject. The invention further relates to a cell culture mineralization model comprising a culture of an extracellular matrix producing cell under conditions that support extracellular matrix formation and matrix maturation, a test compound, and means and methods for determining in expression levels of genes encoding matrix proteins.Type: GrantFiled: November 16, 2007Date of Patent: March 24, 2015Assignee: Arcarios B.V.Inventors: Johannes Petrus Thomas Maria Van Leeuwen, Hermanus Johannes Marco Eijken
-
Patent number: 8987204Abstract: It is an object of the present invention to provide a bone regeneration agent and a bone supplementation formulation, in which a supplementation material itself is capable of promoting bone regeneration. The present invention provides a bone regeneration agent which comprises a gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen.Type: GrantFiled: September 3, 2010Date of Patent: March 24, 2015Assignee: FUJIFILM CoporationInventors: Takahiro Hiratsuka, Shouji Ooya, Ichiro Nishimura
-
Publication number: 20150080312Abstract: This invention relates to an isolated, compound of Formula (1) or derivatives or pharmaceutically acceptable salts thereof. The invention also includes all isomeric and tautomeric forms of the compound of Formula (1) or the derivatives thereof. The present invention further relates to processes for the production of the compound of Formula (1) by fermentation of the fungal strain of Actinomycetes (PM0895172/MTCC 684), pharmaceutical compositions comprising the compound of Formula (1) as the active ingredient; and use of the compounds or composition containing them in the treatment of cancer.Type: ApplicationFiled: May 6, 2013Publication date: March 19, 2015Applicant: PIRAMAL ENTERPRISES LIMITEDInventors: Prabhu Dutt Mishra, Sreekumar Sankaranarayanan Eyyammadichiyl, Saji David George, Shailendra Sonawane, Narayan Subhash Chakor, Abhijit Roychowdhury, Rajiv Sharma
-
Publication number: 20150073476Abstract: The present invention relates to compositions comprising shape memory polymer (SMP) materials and uses thereof. Particularly, although not exclusively, the present invention relates to biocompatible shape memory polymer (SMP) materials and uses thereof in the medical field.Type: ApplicationFiled: October 5, 2012Publication date: March 12, 2015Inventors: Malcolm Brown, Horacio Montes de Oca Balderas, Michael Andrew Hall, Alan William Bull, David Franklin Farrar, Philip Caton-Rose, Philip David Coates, Glen Thompson, Michael Martyn, Ian MacMillan Ward, Mark James Bonner, Peter John Hine, Paul Unwin, Robin Anthony Chivers, Michael Woodhead
-
Patent number: 8975231Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: June 1, 2012Date of Patent: March 10, 2015Assignees: The Regents of the University of California, The United States of America represented by the Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Brochmann-Murray, Jeffrey Wang, Keyvan Behnam
-
Patent number: 8969296Abstract: The present invention relates to a GFP-CAP peptide having an amino acid sequence derived from TGF-?1 (transforming growth factor-?1) and a cell adhesion sequence, wherein the amino acid sequence derived from TGF-?1 consists of the amino acid sequence of SEQ ID NO:1 and the TGFP-CAP peptide is represented by the following formula I: Ile-Trp-Ser-Leu-Asp-Thr-Gln-Tyr-Cell adhesion sequence (I). The TGFP-CAP peptide of the present invention exhibits excellent anti-angiogenic activity. In addition, the TGFP-CAP peptide of the present invention prevents effectively melanin generation in skin to have skin whitening effects. The present peptide shows much higher stability and permeability to skin than natural-occurring TGF-?1. Such plausible activities and safety of the present peptide enable advantageously to application to drugs, quasi-drugs and cosmetics.Type: GrantFiled: September 12, 2007Date of Patent: March 3, 2015Assignee: Caregen Co., LtdInventors: Yong-Ji Chung, Young Deug Kim, Eun Mi Kim, Jun Young Choi, Jin Seuk Kim, Sang Su Song, Kyoung Mi Cho
-
Publication number: 20150056163Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.Type: ApplicationFiled: August 25, 2014Publication date: February 26, 2015Inventors: Victor J. Torres, Derya Unutmaz, Francis Alonzo, III
-
Publication number: 20150051138Abstract: Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to treat infectious diseases, cancers, and inflammatory/autoimmune disorders, are also disclosed.Type: ApplicationFiled: March 14, 2013Publication date: February 19, 2015Applicant: Sanford-Burnham Medical Research InstituteInventors: Alex Strongin, Maurizio Pellecchia, Elisa Barile
-
Publication number: 20150045304Abstract: The invention relates to peptides including DEDE(SSD)nDEG indicated by SEQ NO. 1, RRRDEDE(SSD)nDEG indicated by SEQ No. 2, RRRGDEDE(SSD)nDEG indicated by SEQ No. 3, and LKKLKKLDEDE(SSD)nDEG indicated by SEQ NO. 4, wherein n is an integer from 2 to 20. The invention also relates to phosphorylating these peptides at multiple amino acid sites by employing casein kinases. These phosphorylated peptides may be used in various applications such as forming mineralized collagen fibrils and biometic composites for use in tissue repair and regeneration.Type: ApplicationFiled: November 13, 2013Publication date: February 12, 2015Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: ELIA BENIASH, CHARLES S. SFEIR